Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma MELANI-01
Verified

What's the purpose of this trial?

This is a Phase I, FIH, open-label, dose escalation study evaluating safety and efficacy of UCART targeting CS1 in patients with relapsed or refractory multiple myeloma (MM). The purpose of this study is to evaluate the safety and clinical activity of one infusion of UCARTCS1A and to determine the Maximum Tolerated Dose (MTD).

This trial is currently open and accepting patients.


What will happen during the trial?

On July 7, 2020, the FDA placed a clinical hold on this clinical trial based on a safety issue in one patient enrolled at the study at dose level two. Learn more

Additional Trial Information

Phase 1

Enrollment: 18 patients (estimated)

View More

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.

New Jersey

John Theurer Cancer Center Hackensack Meridian Health

Hackensack, NJ

Open and Accepting

Texas

MD Anderson Cancer Center The University of Texas

Houston, TX

Open and Accepting

Trial Links

Read the latest news and updates on this trial.

Cellectis' CAR-T Trial for Multiple Myeloma on Clinical Hold After Patient Death

July 07, 2020

Cellectis, based in Paris and New York, announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its MELANI-01 trial.

Read more
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message

SparkCures Verified

SparkCures is working closely with Cellectis S.A. to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.

Learn more about how we work with trial sponsors